European Respiratory Society Annual Congress 2012

Abstract Number: 2308 Publication Number: P2294

Abstract Group: 5.2. Monitoring Airway Disease Keyword 1: Allergy Keyword 2: Asthma - diagnosis Keyword 3: Asthma - management

Title: The German severe asthma register

Dr. Stephanie 16076 Korn Stephanie.Korn@unimedizin-mainz.de MD ¹, Dr. Marisa 16077 Hübner marisa.huebner@unimedizin-mainz.de MD ¹, Prof. Karl-Christian 16078 Bergmann karlchristianbergmann@googlemail.com MD ², Dr. Antje 16079 Jahn antje.jahn@unimedizin-mainz.de ³, Dr. Peter 16080 Kardos pkardos@aol.com MD ⁴, Dr. Andrea 16088 Koch andrea.koch@bergmannsheil.de MD ⁵, Dr. Marek 16094 Lommatzsch marek.lommatzsch@gmx.de MD ⁶, Prof. Eckhard 16095 Hamelmann e.hamelmann@klinikum-bochum.de MD ⁷ and Prof. Roland 16097 Buhl roland.buhl@unimedizin-mainz.de MD ¹. ¹ Pulmonary Dept., Mainz University Hospital, Mainz, Germany ; ² Allergy-Centre-Charité, Charité – Universitätsmedizin Berlin, Berlin, Germany ; ³ IMBEI, Mainz University Hospital, Mainz, Germany ; ⁴ Lungenpraxis Maingau, Lungenpraxis Maingau, Frankfurt, Germany ; ⁵ Pulmonary Dept., University Hospital Bergmannsheil, Bochum, Germany ; ⁶ Pulmonary Dept., Rostock University Hospital, Rostock, Germany and ⁷ Children's Hospital, Ruhr University, Bochum, Germany .

Body: Patients with severe persistent asthma represent the highest unmet medical need among the asthmatic population today. To improve the understanding of more severe disease progresses in pediatric and adult asthma the German Asthma Net (GAN e.V.) launched a National Severe Asthma Register in December 2011. Enrolled patients undergo detailed clinical and physiologic evaluations, including patients' medical history, allergy, lung function, lung inflammation, blood testing as well as past and concomitant medication and comorbidities. As of February 20, 2012 six participating centers joined the program and recruited 93 subjects (mean age±SEM 49±1 years, 63% female, FEV1 2.0±0.1 L (65.3±2.1%), 97% uncontrolled or partly controlled asthma according to GINA, 54% allergic asthma, 46% on oral corticosteroids, 39% on omalizumab, eNO 51±6 ppb, 3.4±0.4 exacerbations during the last 12 months). Recruitment of a larger number of subjects with severe asthma, including children, is ongoing and will allow further characterization of clinical, physiologic, cellular and biochemical factors related to severe disease in a longitudinal assessment to identify parameters that improve diagnosis, phenotyping, management and treatment of this heterogeneous condition. In addition, the German Severe Asthma Register may help to confirm and extend results obtained in similar databases, including U-BIOPRED and SARP.